Ask HopeStage to review this study with me
Study ID: NCT06278532. We help you review the study, but cannot decide medical eligibility.
RecruitingNCT06278532
Validation of the Lithuanian Version of the BNSS, CDSS, and the SCoRS
This study is recruiting. It focuses on schizophrenia and currently lists participation information in Lithuania.
Schizophrenia, Depression, ...Diagnostic TestFrom 18 Years to 65 Years
Key information made simple
What is this study testing?
This study is testing whether the study approach may be useful for adults experiencing schizophrenia.
What would participation involve?
Participants may complete study activities around the study approach, complete questionnaires or follow-up assessments, attend study visits with the research team. The registry lists locations in Lithuania.
Who is it mainly for?
This study appears to be mainly for adults with schizophrenia.
What should you check before joining?
Ask about whether there is a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
The official record suggests in-person participation through a hospital, with sites including Lithuanian University of Health Sciences Hospital Kaunas Clinics and Jonas Montvidas in Kaunas. Participation appears to center on assessments, scans, or samples rather than trying a new treatment. The main fit is usually matching the main diagnosis and being able to understand the study and consent, while common reasons not to take part include active substance or alcohol problems that could affect the results and other factors that could make participation unsuitable. The official record does not list a trial phase, which usually means the study is focused on observation rather than testing a staged treatment.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
Study start dateStarted: December 11, 2023
- Recruitment status
- Recruiting
- Estimated enrollment
- Not clearly listed
- Sponsor
- Lithuanian University of Health Sciences
- Sponsor type
- University
- Study type
- Diagnostic Test
- Intervention type
- Biological / biomarker / imaging
- Study phase
- Not clearly listed
- Locations
- Lithuania
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06278532
- Official title
- Validation of the Lithuanian Version of the BNSS, CDSS, and the SCoRS
- Official source
- Official registry link
Want help reviewing this study?
Study ID: NCT06278532. We help you review the study, but cannot decide medical eligibility.
For you
Taking part may help clarify how this condition is measured or understood.
It requires regular follow-up, often through questionnaires or interviews.
Requires travel, with in-person participation in Lithuania.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is this study trying to understand?
This study is exploring blood test or biological sample for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve biological samples, imaging, or biomarkers?
This appears to be a biological / biomarker / imaging study. The phase is not clearly listed in the public registry. Phase is mostly relevant for medication studies and some device studies. For this study, it may be more useful to look at what is required, the duration, visits, and eligibility criteria.
Do I need to want to stop or reduce tobacco use to participate?
The public registry appears to mention tobacco, nicotine, alcohol, cannabis, or another addiction-related topic. Ask the study team whether you need to want to stop, reduce, already be abstinent, or simply meet use-related criteria. Eligibility must be confirmed by the study team.
What would I likely need to do?
You may need to provide biological samples, complete lab tests, or take part in imaging or measurement procedures. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What should I check about samples, imaging, data, and possible discomfort?
If the study involves samples, imaging, or biomarkers, ask what is collected, how it is stored, who can access results, whether there may be discomfort, and whether results are shared with you. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Lithuanian University of Health Sciences, which appears to be a university. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The registry indicates that this study is currently recruiting. This does not mean you are eligible: the study team must confirm the criteria, available locations, and next steps.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
RecruitingISRCTN33909010
Placebo- and active comparator-controlled, study to study the safety and efficacy of two doses of lurasidone HCL in acutely psychotic people with schizophrenia
This study is recruiting in the United Kingdom, in Bulgaria, in Colombia, .... It focuses on schizophrenia.
RecruitingNCT06966401
NBI-1065845 for depression
This study is recruiting in the United States, in the United Kingdom, in Belgium, .... It is testing NBI-1065845 for depression.
RecruitingNCT05850689
Lumateperone as Adjunctive Therapy in the Treatment of people with Major Depressive Disorder
This study is recruiting. It focuses on depression and currently lists participation information in Bulgaria, France, India, Lithuania, Serbia, Spain, and the United States.